Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 5/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | PIK3R5 | Q8WYR1 | 1/20 | 0.37 |
| ▸ | PIK3R3 | Q92569 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2187138 | 0.83 | CNR2 (0.57) | CNR2CNR1 | |
| SCHEMBL2185250 | 0.82 | CNR2 (0.58) | CNR2CNR1 | |
| SCHEMBL2187831 | 0.82 | CNR2 (0.54) | CNR2CNR1 | |
| SCHEMBL4783557 | 0.76 | CYP1A2 (0.47) | RAD52CNR1CCNA2CDK2CCNA1 | |
| SCHEMBL2186060 | 0.75 | CNR1 (0.58) | CNR2CNR1 | |
| SCHEMBL2492413 | 0.74 | CNR2 (0.52) | CNR2CNR1 | |
| SCHEMBL16161285 | 0.72 | CNR2 (0.59) | CNR2CNR1 | |
| SCHEMBL2186048 | 0.72 | CNR2 (0.73) | CNR2CNR1 | |
| SCHEMBL2186076 | 0.71 | CNR2 (0.74) | CNR2CNR1 | |
| SCHEMBL2185163 | 0.71 | CNR2 (0.68) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030345-B2 | Tricyclic pyrazole derivatives as cannabinoid receptor modulators | CADILA HEALTHCARE LIMITED (IN) | 2011-10-04 | — | — | US | claimed |
| EP-2343302-A1 | TRICYCLIC PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CADILA HEALTHCARE LIMITED (IN) | 2011-07-13 | — | — | EP | claimed |
| US-20100273791-A1 | TRICYCLIC PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CADILA HEALTHCARE LIMITED | 2010-10-28 | — | — | US | claimed |
| US-8030345-B2 | Tricyclic pyrazole derivatives as cannabinoid receptor modulators | CADILA HEALTHCARE LIMITED (IN) | 2011-10-04 | — | — | US | disclosed |
| EP-2343302-A1 | TRICYCLIC PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CADILA HEALTHCARE LIMITED (IN) | 2011-07-13 | — | — | EP | disclosed |
| US-20100273791-A1 | TRICYCLIC PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CADILA HEALTHCARE LIMITED | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273791-A1 | TRICYCLIC PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, GPR55 | CNR2 1/4885RAD52 4722/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.